Roche ups the ante in obesity
12/03/25 -"Roche and Zealand Pharma have agreed to co-develop and co-commercialise Zealand’s phase II weight-loss drug candidate, petrelintide, as monotherapy and in combination with Roche’s ..."
Pages
65
Language
English
Published on
12/03/25
You may also be interested by these reports :
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum
20/08/25
Following Donald Trump’s tariff threats and given the generic/biosimilar medicine makers’ relatively thin profitability, the markets were quick to ...